Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
This announcement underscores Regentis’ commitment to addressing a significant unmet need in orthopedic care. According to the company, GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available. The European market presents a similar opportunity, and the training program is designed to ensure that surgeons are proficient in the implantation technique, which is critical for achieving optimal patient outcomes.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. Unlike current treatments that often require cell harvesting or multiple surgeries, GelrinC offers a single-step procedure that could reduce recovery time and improve outcomes for patients with knee cartilage lesions.
The training sessions will be conducted at Humanitas Research Hospital in Milan, a renowned center for orthopedic research and treatment. Additional sessions are planned across Europe to ensure broad access for surgeons interested in adopting the technology. The company has not disclosed specific dates for the training but expects them to commence in Q3 2026.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The company's lead product, GelrinC, is CE Mark-approved and represents a potential paradigm shift in knee cartilage repair.
For more information on the full press release, visit https://ibn.fm/QOWWK. Additional details about the company and its technology can be found on the Regentis Biomaterials website.
